Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant FLOT versus FLOT + sintilimab versus FLOT + sintilimab + apatinib for locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200063760Phase 2Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib, sintilimab and FLOT in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: pathological complete response rate. Started Aug 2022; status: recruiting.
02
Drugs
RivoceranibsintilimabFLOT
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200063760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063760.